• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
January 27, 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
January 17, 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
January 17, 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
January 13, 2025
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
December 11, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
December 09, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
December 08, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
December 06, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 05, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
November 25, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
November 20, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
November 12, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca’s 9M and Q3 2024 results
November 12, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
November 08, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
November 07, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
October 07, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
October 03, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
October 01, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
September 26, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 23, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
FLUMIST approved for self-administration in the US
September 20, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
September 18, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
September 16, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
September 15, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
September 13, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 09, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 08, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
September 03, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
August 16, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
August 15, 2024
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap